Trials to Continue on Promising Drug for some Lymphoma Patients

An important clinical trial for patients with relapsed or refractory Hodgkin lymphoma who have previously been given autologous stem cell transplants is scheduled to begin in early 2009 under the auspices of Seattle Genetics (www.seagen.com). They will enroll 100 patients in the US, Canada and Europe.



The trial will test the efficacy of a drug currently called SGN-35, an antibody-drug conjugate (ADC) that, once it gets inside CD30-expressing tumor cells, releases monomethyl auristatin E (MMAE), which kills those cells.



They also plan to begin a phase II study of SGN-35 in early 2009 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL).



The President and CEO of Seattle Genetics told therapeuticsdaily.com, “The data thus far from both of our phase I trials of SGN-35 have exceeded our expectations … suggesting that this agent may address a substantial unmet medical need in patients with relapsed or refractory Hodgkin lymphoma.”



Provided the trials go well, Seattle Genetics intends to submit an accelerated new drug application to the FDA for SGN-35 in 2011.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap